A meta-analysis of everolimus-eluting stents versus sirolimus-eluting stents and paclitaxel-eluting stents in diabetic patients

Table 1 Baseline characteristics of the included trials

Trial	Published years	Comparison arms	Sample size	Follow-up, months	DAPT duration, months	Mean age, years	Male, %	Insulin use, %	ACS, %	Primary endpoint	Current smoker, %	BMI
BIOSCIENCE	2015	EES vs SES	229/257	12	12	68	76	32.9	45	Target lesion failure, Cardiac death, TV-MI, TLR	22	29.5
DiabeDES IV	2015	EES vs SES	108/105	48	12	63	NR	NR	31.9	In-stent late luminal loss	23	29.5
RACES-MI	2015	EES vs SES	64/68	36	12	61	68	37.1	NR	MACE	26	NR
ESSENCE-DIABETES	2011	EES vs SES	149/151	12	12	64	59	15.3	42	In-stent late loss	24	NR
ISAR-TEST-4 Trial	2013	EES vs SES	184/193	36	6	68	74	32.4	40	Cardiac mortality, TV-MI, TLR	14.3	NR
SORT OUT IV	2012	EES vs SES	194/196	18	12	64	74	32.1	33	Cardiac mortality, MI, ST, TVR	22.8	NR
SPIRIT V	2012	EES vs PES	215/104	12	6	65	43	17.2	37	In-stent late loss	16.4	NR
Tuxedo	2017	EES vs PES	916/914	24	12	58	75	40.8	53	TVF, TV-MI, TVR	15	26

DAPT dual antiplatelet therapy, ACS acute coronary syndrome, BMI body mass index, EES everolimus-eluting stents, PES paclitaxel-eluting stents, MI myocardial infarction, TLR target-lesion revascularization, MACE major adverse cardiac events, TV target-vessel, TVR target-vessel revascularization, ST stent thrombosis, TVF target vessel failure NR not reported

ISSN: 1749-8090